Pictured: Eric Timm and Dr Ross O’Neill (CEO)
In 2020, it was announced that Irish med-tech company raised €10.5 million to fund their expansion. The company in question, Neuromod Devices, produces non-invasive technology to aid with tinnitus. Planning to pump funds into their sales and marketing department, the company will recruit an additional 40 employees.
Neuromod Devices Ltd has appointed Ms. Teri Minard, Director of Government Sales. Another appointment at same is Eric Timm, as Chief Executive Officer, where he will lead the US business. Bringing a wealth of experience, Mr. Timm has over 35 years experience in leadership positions, previously holding roles such as President and Chief Executive Officer of the company’s US wholesale business. Additionally, Diarmuid Flavin was recently appointed Chief Operating Officer, bringing more than 25 years global leadership experience in a range of medical devices, technology, and pharmaceutical companies. In August, Susan Whicard was appointed as a non-executive board member of the company. Susan, a US native, has a background as a clinical audiologist, establishing her own practice.
Neuromod USA Inc. is a wholly owned subsidiary of Neuromod Devices Ltd. The company specializes in non-invasive neuromodulation technologies and has developed Lenire, the first non-invasive bimodal neuromodulation device for the treatment of tinnitus which has been clinically proven in large-scale clinical trials to soothe tinnitus symptoms. To date Neuromod has raised more than €26 million in venture financing to fund ongoing expansion of the availability of Lenire in Europe and the organisation’s FDA submission process in the US.
Lenire uses bimodal neuromodulation to treat tinnitus symptoms. It delivers mild electrical pulses to the tongue combined with sound played through headphones to drive long-term changes or neuroplasticity in the brain to treat tinnitus.